On November 25, 2020 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported that the collaboration and license agreement between Arrowhead and Takeda Pharmaceutical Company Limited announced on October 8, 2020, has now closed (Press release, Arrowhead Pharmaceuticals, NOV 25, 2020, View Source [SID1234571747]). Closing of the transaction was contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the U.S.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!